POINT BIOPHARMA GLOBAL INC.

PNTUnited States

15 filed reports · 330 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$227M

FY2022 · to Dec 31, 2022

a year earlier: $0

10-K

Net income

$98.3M

FY2022 · to Dec 31, 2022

a year earlier: -$45.9M

10-K

Operating income

$126M

FY2022 · to Dec 31, 2022

a year earlier: -$45.5M

10-K

Latest quarter

Revenue

$2.79M

Q3 FY2023 · to Sep 30, 2023

a year earlier: $0

10-Q

Net income

-$24.8M

Q3 FY2023 · to Sep 30, 2023

a year earlier: -$24M

10-Q

Operating income

-$29.6M

Q3 FY2023 · to Sep 30, 2023

a year earlier: -$24.6M

10-Q

Filed reports

15 reports · Jun 2020 to Sep 2023

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR111,275Jun 2020 to Sep 2023
Annual · 10-KSEC EDGAR3668Dec 2020 to Dec 2022
Registration · S-1SEC EDGAR1168Jul 2021

Documents

PeriodTypePeriod endPublishedFactsSource
FY2023 Q310-Q2023-09-302023-11-13352Open
FY2023 Q210-Q2023-06-302023-08-14163Open
FY2023 Q110-Q2023-03-312023-05-15154Open
FY202210-K2022-12-312023-03-27429Open
FY2022 Q310-Q2022-09-302022-11-14128Open
FY2022 Q210-Q2022-06-302022-08-12112Open
FY2022 Q110-Q2022-03-312022-05-1391Open
FY202110-K2021-12-312022-03-25215Open
FY2021 Q310-Q2021-09-302021-11-1286Open
FY2021S-12021-07-302021-07-30168Open
FY2021 Q210-Q2021-06-302021-08-1371Open
FY2021 Q110-Q2021-03-312021-04-2969Open

Financial data

330 concepts · 2,111 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial329 concepts · 2,107 facts · Dec 2019 to Sep 2023

  • Cash cash equivalents restricted cash and restricted cash equivalents20 · Dec 2019 to Sep 2023
  • Stockholders equity including portion attributable to noncontrolling interest20 · Dec 2019 to Sep 2023
  • Assets19 · Dec 2019 to Sep 2023
  • Assets current19 · Dec 2019 to Sep 2023
  • Foreign currency transaction gain loss before tax19 · Dec 2019 to Sep 2023
  • Liabilities and stockholders equity19 · Dec 2019 to Sep 2023
  • Liabilities current19 · Dec 2019 to Sep 2023
  • Payments of dividends common stock19 · Dec 2019 to Sep 2023
  • Retained earnings accumulated deficit19 · Dec 2019 to Sep 2023
  • Adjustments to additional paid in capital share based compensation stock options requisite service period recognition18 · Mar 2020 to Sep 2023
  • Cash and cash equivalents at carrying value18 · Dec 2019 to Sep 2023
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect18 · Mar 2020 to Sep 2023
  • Common stock par or stated value per share18 · Dec 2019 to Sep 2023
  • General and administrative expense (US GAAP)18 · Mar 2020 to Sep 2023
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest18 · Mar 2020 to Sep 2023
  • Income tax expense benefit18 · Mar 2020 to Sep 2023
  • Increase decrease in accounts payable trade18 · Mar 2020 to Sep 2023
  • Increase decrease in accrued liabilities18 · Mar 2020 to Sep 2023
  • Increase decrease in prepaid deferred expense and other assets18 · Mar 2020 to Sep 2023
  • Interest income expense net18 · Mar 2020 to Sep 2023
  • Liabilities18 · Dec 2019 to Sep 2023
  • Net cash provided by used in financing activities18 · Mar 2020 to Sep 2023
  • Net cash provided by used in operating activities18 · Mar 2020 to Sep 2023
  • Net income loss18 · Mar 2020 to Sep 2023

Product1 concept · 4 facts · Dec 2021 to Dec 2022

  • Revenue4 · Dec 2021 to Dec 2022

Segments

4 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service2 members · 4 facts

  • License revenue2 · Dec 2021 to Dec 2022
  • Other revenue2 · Dec 2021 to Dec 2022

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of POINT BIOPHARMA GLOBAL INC. (PNT) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.